Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update

References

• Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31(1), 1–20 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med. 361(21), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Dahan S, Roth-Walter F, Arnaboldi P, Agarwal S, Mayer L. Epithelia: lymphocyte interactions in the gut. Immunol. Rev. 215, 243–253 (2007).
   PubMed Web of Science ®Google Scholar
• Neurath MF. IL-23: a master regulator in Crohn disease. Nature Med. 13(1), 26–28 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN et al.; Ustekinumab Crohn’s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135(4), 1130–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 32(8), 913–917 (1991).
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor α in stool as a marker of intestinal inflammation. Lancet 339(8785), 89–91 (1992).
   PubMed Web of Science ®Google Scholar
• Danese S, Semeraro S, Marini M et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis. 37(11), 811–818 (2005).
   PubMedGoogle Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 128(2), 376–392 (2005).
   PubMed Web of Science ®Google Scholar
• Vudattu NK, Holler E, Ewing P et al. Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells. Immunology 115(4), 536–543 (2005).
   PubMed Web of Science ®Google Scholar
• Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol. 164(12), 6193–6198 (2000).
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 58(5), 1248–1257 (2008).
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 110(6), 673–687 (2002).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7(3), 251–259 (1995).
   PubMed Web of Science ®Google Scholar
• Miheller P, Lakatos PL, Horváth G et al. Efficacy and safety of infliximab induction therapy in Crohn’s disease in Central Europe – a Hungarian nationwide observational study. BMC Gastroenterol. 9, 66 (2009).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Colombo E, Maconi G et al. Infliximab in treatment of Crohn’s disease: the Milan experience. Dig. Liver Dis. 34(6), 411–418 (2002).
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis. 15(9), 1295–1301 (2009).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362(15), 1383–1395 (2010).
   PubMed Web of Science ®Google Scholar
• Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin. Biol. Ther. 12(2), 179–192 (2012).
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns Colitis 4(4), 355–366 (2010).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348(7), 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panes J, García V et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose ‘escalation’ in patients losing response. J. Clin. Gastroenterol. 45(2), 113–118 (2011).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am. J. Gastroenterol. 104(3), 760–767 (2009).
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin. Gastroenterol. Hepatol. 4(10), 1248–1254 (2006).
   PubMed Web of Science ®Google Scholar
• Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn’s disease. Dis. Colon Rectum 24(1), 22–24 (1981).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med. 340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn’s disease. Dig. Dis. Sci. 54(8), 1746–1752 (2009).
   PubMed Web of Science ®Google Scholar
• Bouguen G, Trouilloud I, Siproudhis L et al. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment. Pharmacol. Ther. 30(7), 749–756 (2009).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med. 350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Karmiris K, Bielen D, Vanbeckevoort D et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn’s disease by using magnetic resonance imaging. Clin. Gastroenterol. Hepatol. 9(2), 130–136 (2011).
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am. J. Gastroenterol. 104(12), 2973–2986 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz DA. Editorial: Imaging and the treatment of Crohn’s perianal fistulas: to see is to believe. Am. J. Gastroenterol. 104(12), 2987–2989 (2009).
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 136(2), 441–450.e1; quiz 716 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Fukunaga K, Ikeuchi H et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm. Bowel Dis. 18(9), 1617–1623 (2012).
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 49(7), 1215–1228 (2010).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130(2), 323–333; quiz 591 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial. Am. J. Gastroenterol. 104(5), 1170–1179 (2009).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Hanauer SB, Panaccione R et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease. Aliment. Pharmacol. Ther. 34(3), 306–317 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 137(5), 1628–1640 (2009).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Vermeire S, Ballet V et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 61(2), 229–234 (2012).
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis. 13(11), 1323–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al.; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med. 357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin. Gastroenterol. Hepatol. 9(8), 670–678.e3 (2011).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. 357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OØ, Schreiber S et al.; Precise 3 Study Investigators. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin. Gastroenterol. Hepatol. 8(7), 600–609 (2010).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study. Aliment. Pharmacol. Ther. 33(2), 185–193 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D’Haens G et al. Certolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximab. Clin. Gastroenterol. Hepatol. 8(8), 688–695.e2 (2010).
   PubMed Web of Science ®Google Scholar
• Allez M, Vermeire S, Mozziconacci N et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment. Pharmacol. Ther. 31(1), 92–101 (2010).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Rutgeerts P et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm. Bowel Dis. 18(2), 201–211 (2012).
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7), 1805–1811 (2005).
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J et al. Cyclosporine A vs. infliximab in severe acute UC refractory to IV steroids: a randomized trial. Presented at: Digestive Diseases Week, Chicago, IL, USA, 7–10 May 2011.
   Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60(6), 780–787 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2), 257–65.e1 (2012).
   PubMed Web of Science ®Google Scholar
• Shealy D, Cai A, Staquet K et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs 2(4), (2010).
   PubMedGoogle Scholar
• Sandborn W, Feagan B, Marano C et al. A Phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Presented at: Digestive Diseases Week, San Diego, CA, USA, 19–22 May 2012.
   Google Scholar
• Rojas JR, Taylor RP, Cunningham MR et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 313(2), 578–585 (2005).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin. Gastroenterol. Hepatol. 2(7), 542–553 (2004).
   PubMed Web of Science ®Google Scholar
• Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59(1), 49–54 (2010).
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105(5), 1133–1139 (2010).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134(7), 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. Presented at: ECCO-IBD, Dublin, Ireland, 24–26 February 2011.
   Google Scholar
• Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63–70 e5; quiz e31 (2012).
   PubMed Web of Science ®Google Scholar
• Waugh AW, Garg S, Matic K et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32(9), 1129–1134 (2010).
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand. J. Gastroenterol. 47(5), 518–527 (2012).
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn’s disease. Gastroenterology 121(2), 268–274 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH et al.; Natalizumab Pan-European Study Group. Natalizumab for active Crohn’s disease. N. Engl. J. Med. 348(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R et al.; International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 353(18), 1912–1925 (2005).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN et al.; International Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 132(5), 1672–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med. 352(24), 2499–2507 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin. Gastroenterol. Hepatol. 6(12), 1370–1377 (2008).
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled Phase 2 dose-ranging study. Inflamm. Bowel Dis. 18(8), 1470–1479 (2012).
   PubMed Web of Science ®Google Scholar
• Feagan B, Rutgeerts P, Sands B et al. Induction therapy for ulcerative colitis: Results of GEMINI 1, a randomized placebo-controlled, double-blind multi-center Phase 3 Trial. Presented at: Digestive Diseases Week, San Diego, CA, USA, 19–22 May 2012.
   Google Scholar
• Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology 20(1), 1–18 (2012).
   PubMedGoogle Scholar
• Rutgeerts PJ, Fedorak RN, Hommes DW et al. A randomised Phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis. Gut doi:10.1136/gutjnl-2011-301769 (2012) (Epub ahead of print).
   Google Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn’s disease. IDrugs 13(7), 472–781 (2010).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL et al. A multicenter, randomized, double-blind, placebo-controlled Phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn’s disease: key results through week 22 from the CERTIFI trial. Presented at: Digestive Diseases Week, Chicago, IL, USA, 7–10 May 2011.
   Google Scholar
• Sandborn WJ, Ghosh S, Panes J et al.; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367(7), 616–624 (2012).
   PubMed Web of Science ®Google Scholar
• Van Assche G, Sandborn WJ, Feagan BG et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55(11), 1568–1574 (2006).
   PubMed Web of Science ®Google Scholar
• Reinisch W, de Villiers W, Bene L et al. Fontolizumab in moderate to severe Crohn’s disease: a Phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16(2), 233–242 (2010).
   PubMed Web of Science ®Google Scholar
• Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7(5), 617–632 (2008).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58(4), 501–508 (2009).
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum. 52(10), 2968–2974 (2005).
   PubMedGoogle Scholar
• Van Assche G, Lewis JD, Lichtenstein GR et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: safety. Am. J. Gastroenterol. 106(9), 1594–602; quiz 1593, 1603 (2011).
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm. Bowel Dis. doi:10.1002/ibd.23011 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N. Engl. J. Med. 353(4), 432–433 (2005).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366(20), 1870–1880 (2012).
   PubMed Web of Science ®Google Scholar
• Trampe AK, Hemmelmann C, Stroet A et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology78(22), 1736–1742 (2012).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7(8), 874–881 (2009).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4), 242–251 (2007).
   PubMed Web of Science ®Google Scholar